134 related articles for article (PubMed ID: 11106669)
1. HER2 in prostate cancer--a viable target or innocent bystander?
Scher HI
J Natl Cancer Inst; 2000 Dec; 92(23):1866-8. PubMed ID: 11106669
[No Abstract] [Full Text] [Related]
2. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response?
Thor A
J Natl Cancer Inst; 2001 Aug; 93(15):1120-1. PubMed ID: 11481375
[No Abstract] [Full Text] [Related]
3. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
4. Use of an antibody to target geldanamycin.
Mendelsohn J
J Natl Cancer Inst; 2000 Oct; 92(19):1549-51. PubMed ID: 11018081
[No Abstract] [Full Text] [Related]
5. HER-2 profiling and targeting in prostate carcinoma.
Morris MJ; Reuter VE; Kelly WK; Slovin SF; Kenneson K; Verbel D; Osman I; Scher HI
Cancer; 2002 Feb; 94(4):980-6. PubMed ID: 11920466
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
[TBL] [Abstract][Full Text] [Related]
7. [ERBB2/HER2: from molecular to clinical oncology].
Khanson KP; Imianitov EN
Vopr Onkol; 2002; 48(2):137-45. PubMed ID: 12227060
[No Abstract] [Full Text] [Related]
8. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.
Santin AD; Bellone S; Roman JJ; McKenney JK; Pecorelli S
Int J Gynaecol Obstet; 2008 Aug; 102(2):128-31. PubMed ID: 18555254
[TBL] [Abstract][Full Text] [Related]
9. Targeting HER2 in prostate cancer: where to next?
Solit DB; Rosen N
J Clin Oncol; 2007 Jan; 25(3):241-3. PubMed ID: 17235040
[No Abstract] [Full Text] [Related]
10. Targeted cancer therapies attempt to hit the bull's-eye.
Miller M
J Natl Cancer Inst; 2000 Dec; 92(23):1878-9. PubMed ID: 11106678
[No Abstract] [Full Text] [Related]
11. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
13. Re: HER2 testing in the real world.
Vincent-Salomon A; MacGrogan G; Couturier J; Arnould L; Mathoulin-Pélissier S;
J Natl Cancer Inst; 2003 Apr; 95(8):628; author reply 628-9. PubMed ID: 12697858
[No Abstract] [Full Text] [Related]
14. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
Yaziji H; Gown AM
Hum Pathol; 2004 Feb; 35(2):143-6. PubMed ID: 14991529
[No Abstract] [Full Text] [Related]
15. The role of overexpressed HER2 in transformation.
Neve RM; Lane HA; Hynes NE
Ann Oncol; 2001; 12 Suppl 1():S9-13. PubMed ID: 11521729
[TBL] [Abstract][Full Text] [Related]
16. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
17. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.
Ziada A; Barqawi A; Glode LM; Varella-Garcia M; Crighton F; Majeski S; Rosenblum M; Kane M; Chen L; Crawford ED
Prostate; 2004 Sep; 60(4):332-7. PubMed ID: 15264245
[TBL] [Abstract][Full Text] [Related]
18. Experts debate value of HER2 testing methods.
Nelson NJ
J Natl Cancer Inst; 2000 Feb; 92(4):292-4. PubMed ID: 10675369
[No Abstract] [Full Text] [Related]
19. HERe-2 stay: the continuing importance of translational research in breast cancer.
Sledge GW
J Natl Cancer Inst; 2004 May; 96(10):725-7. PubMed ID: 15150294
[No Abstract] [Full Text] [Related]
20. HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
Tanvetyanon T
JAMA; 2004 Jul; 292(3):328; author reply 328-9. PubMed ID: 15265845
[No Abstract] [Full Text] [Related]
[Next] [New Search]
